Paper32405174
Sofosbuvir-Velpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney Transplantation.
Gaur N and 8 others. J Clin Exp Hepatol, 2020. Cited by 22 papers, by iCite.
Cite this record
ConductScience Library. Sofosbuvir-Velpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney Transplantation. Papers, record 32405174. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32405174
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Sofosbuvir-Velpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney Transplantation.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References16
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11684543 | Hepatitis C virus infection and renal transplantation. | Am J Kidney Dis | 2001 | https://conductscience.org/library/papers/11684543 | PubMed |
| 2 | 31195062 | Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. | J Hepatol | 2019 | https://conductscience.org/library/papers/31195062 | PubMed |
| 3 | 26571066 | Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26571066 | PubMed |
| 4 | 20861806 | Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. | Transplantation | 2010 | https://conductscience.org/library/papers/20861806 | PubMed |
| 5 | 20368926 | Prevalence and associations of hepatitis C viremia in hemodialysis patients at a tertiary care hospital. | Indian J Nephrol | 2009 | https://conductscience.org/library/papers/20368926 | PubMed |
| 6 | 26952005 | Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. | J Hepatol | 2016 | https://conductscience.org/library/papers/26952005 | PubMed |
| 7 | 25314116 | Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. | Hepatology | 2015 | https://conductscience.org/library/papers/25314116 | PubMed |
| 8 | 25755548 | Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India. | J Clin Exp Hepatol | 2014 | https://conductscience.org/library/papers/25755548 | PubMed |
| 9 | 28267700 | Ultrasonography for Noninvasive Assessment of Portal Hypertension. | Gut Liver | 2017 | https://conductscience.org/library/papers/28267700 | PubMed |
| 10 | 26575258 | Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26575258 | PubMed |
| 11 | 22537436 | Noninvasive methods to assess liver disease in patients with hepatitis B or C. | Gastroenterology | 2012 | https://conductscience.org/library/papers/22537436 | PubMed |
| 12 | 27924080 | Global epidemiology and burden of HCV infection and HCV-related disease. | Nat Rev Gastroenterol Hepatol | 2017 | https://conductscience.org/library/papers/27924080 | PubMed |
| 13 | 28165830 | Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection. | Expert Opin Drug Metab Toxicol | 2017 | https://conductscience.org/library/papers/28165830 | PubMed |
| 14 | 29270489 | Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen. | Kidney Int Rep | 2017 | https://conductscience.org/library/papers/29270489 | PubMed |
| 15 | 15149347 | Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. | Kidney Int | 2004 | https://conductscience.org/library/papers/15149347 | PubMed |
| 16 | 30675443 | KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. | Kidney Int Suppl (2011) | 2018 | https://conductscience.org/library/papers/30675443 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41305445 | Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes. | Viruses | 2025 | https://conductscience.org/library/papers/41305445 | PubMed |
| 41126716 | 2025 KASL clinical practice guidelines for management of hepatitis C. | Clin Mol Hepatol | 2026 | https://conductscience.org/library/papers/41126716 | PubMed |
| 39131108 | A Quick and Sensitive LC-MS/MS Method for Simultaneous Quantification of Sofosbuvir Metabolite (GS-331007) in Human Plasma: Application to Hepatitis C Infected Patients with End-Stage Renal Disease. | Middle East J Dig Dis | 2024 | https://conductscience.org/library/papers/39131108 | PubMed |
| 38910758 | Efficacy of Sofosbuvir and Velpatasvir Combination in the Treatment of Hepatitis C Virus (HCV) in Chronic Kidney Disease (CKD) Patients. | Cureus | 2024 | https://conductscience.org/library/papers/38910758 | PubMed |
| 38558861 | The Fixed Dose Combination of Sofosbuvir and Velpatasvir is Safe and Effective in Patients of Chronic Hepatitis C With End-stage Renal Disease. | J Clin Exp Hepatol | 2024 | https://conductscience.org/library/papers/38558861 | PubMed |
| 37841743 | The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis. | Front Public Health | 2023 | https://conductscience.org/library/papers/37841743 | PubMed |
| 37657881 | Management of Hepatitis C Virus and Hepatitis B Virus Infection in the Setting of Kidney Disease. | Adv Kidney Dis Health | 2023 | https://conductscience.org/library/papers/37657881 | PubMed |
| 37234437 | Rescue use of Pegylated Interferon in Dialysis Patient who Failed to Respond Sofosbuvir. | Indian J Nephrol | 2023 | https://conductscience.org/library/papers/37234437 | PubMed |
| 36815114 | A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD. | Kidney Int Rep | 2023 | https://conductscience.org/library/papers/36815114 | PubMed |
| 36423179 | Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease. | Viruses | 2022 | https://conductscience.org/library/papers/36423179 | PubMed |
| 35876967 | Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5. | Hepatol Int | 2022 | https://conductscience.org/library/papers/35876967 | PubMed |
| 35649518 | Association of Referral Source and Substance Use with Hepatitis C Virus Outcomes at a Southern Academic Medical Center. | South Med J | 2022 | https://conductscience.org/library/papers/35649518 | PubMed |
| 35369667 | Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease. | Kidney360 | 2021 | https://conductscience.org/library/papers/35369667 | PubMed |
| 34832537 | An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease. | Pathogens | 2021 | https://conductscience.org/library/papers/34832537 | PubMed |
| 33383877 | Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients. | J Clin Med | 2020 | https://conductscience.org/library/papers/33383877 | PubMed |
| 32868869 | Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis. | Sci Rep | 2020 | https://conductscience.org/library/papers/32868869 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32405174
GET https://conductscience.org/api/papers/v1/32405174/authors